8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 26, 2010

HEMACARE CORPORATION

(Exact name of registrant as specified in its charter)

California	000-15223	95-3280412
(State or other jurisdiction	(Commission File Number)	(I.R.S. Employer Identification No.)
of incorporation or organization)

15350 Sherman Way, Suite 350  Van Nuys, California     91406

(Address of principal executive offices)                      (Zip Code)

(Registrant's telephone number, including area code): 818-226-1968

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Page 1

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 26, 2010, John Doumitt, resigned as Chief Executive Officer and Director of HemaCare Corporation ("Registrant").

On February 27, 2010, the Registrant's Board of Directors appointed Pete van der Wal, the Company’s Vice President of Sales and Marketing, as President and Chief Executive Officer.  Mr. van der Wal also was appointed to serve as a member of our Board of Directors, to fill the vacancy created upon Mr. Doumitt’s resignation.

Mr. van der Wal, 53, has been Vice President of Sales and Marketing for HemaCare since November 2009.  Mr. van der Wal is an experienced sales, marketing, operations, and business development professional with more than 20 years of health care experience in the medical services industry.

Prior to joining HemaCare, from May 2008 to November 2009, Mr. van der Wal was President and Chief Executive Officer of Comprehensive Imaging Solutions, a medical imaging equipment refurbishment company.  From 2001 to May 2008, Mr. van der Wal was President and Chief Executive Officer of van der Wal Properties, Inc., a real estate brokerage and remodeling company.  Mr. van der Wal has also held senior management positions at radiology and imaging services companies including Comprehensive Imaging Solutions, Phormax Corporation, Comprehensive Medical Imaging, and Syncor International Corporation. He received his Masters in Business Administration from George Mason University and Bachelor of Science degree from the University of Maryland.

The terms of Mr. van der Wal’s employment remain unchanged from what was set forth in an employment letter, dated November 19, 2009, which agreement provides for:

· base salary of $150,000 per annum;

· eligibility to receive a discretionary bonus of up to $100,000;

· a stock option to purchase up to 75,000 shares of the Company’s common stock at an exercise price of $0.58 per share, which option vests 20% annually starting December 9, 2010 and expires on December 8, 2019; and

· participation in all benefit plans offered to similarly situated employees.

Except as disclosed herein, Mr. van der Wal was not selected pursuant to any arrangement or understanding between Mr. van der Wal or any other person.  There are no family relationships between Mr. van der Wal and the directors or executive officers of the Registrant.

Page 2

Item 7.01. Regulation FD Disclosure.

On March 1, 2010, the Registrant issued a press release announcing the resignation of Mr. Doumitt, and the appointment of Mr. van der Wal as President and Chief Executive Officer, as discussed in Item 5.02 above. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, will not be treated as filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into a filing under the Securities Act of 1933, or into another filing under the Exchange Act, unless that filing expressly refers to specific information in this report.  The furnishing of the information in this Item 7.01 of this Current Report is not intended to and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Item 7.01 contains is material investor information that is not otherwise publicly available.

Item 9.01. Financial Statements and Exhibits.

(d)           Exhibits

Exhibit Number	Description
99.1	Press release dated March 1, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 3, 2010 HEMACARE CORPORATION   By:  /s/ Robert S. Chilton         Robert S. Chilton         Chief Financial Officer

Page 3

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press release dated March 1, 2010.

Page 4

EX-99.1

Exhibit 99.1

N E W S   R E L E A S E

For Immediate Release

Contact: HemaCare Corporation

Robert S. Chilton, Executive Vice President and Chief Financial Officer

877-310-0717

www.hemacare.com

RELEASE DATE:  March 1, 2010

HEMACARE NAMES VAN DER WAL PRESIDENT AND CEO

___________________________________________________________________________________________

LOS ANGELES - HemaCare Corporation (OTC Bulletin Board: HEMA.OB) today announced that its Board of Directors has named Pete van der Wal as President and Chief Executive Officer effective immediately.  He replaces John Doumitt, who resigned from the positions as well as from the Company’s Board of Directors effective February 26, 2010. Van der Wal, who also joins the Company’s Board of Directors, was previously HemaCare’s Vice President, Sales & Marketing. His previous positions included senior Sales, Marketing, Operations and Business Development roles at Syncor International, as well as President and CEO of Comprehensive Imaging Solutions.

Commenting on the appointment, Steven Gerber, M.D., HemaCare’s Chairman, stated, “I am delighted that Pete has accepted this position.  Having worked with Pete at Syncor before he joined HemaCare, and having seen him in action since his arrival at HemaCare, I am confident that his leadership will enable the Company to build on its solid foundation of excellent customer service to achieve sustained growth and profitability”.

About HemaCare Corporation

Founded in 1978, HemaCare Corporation is a provider of blood products and therapeutic services to the healthcare industry.  Licensed by the FDA and accredited by the AABB, the Company focuses on the customized collection and delivery of human blood-related products.  For more information about the Company, visit http://www.hemacare.com.

Safe Harbor Provision

This press release contains forward-looking statements made in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this news release include statements that Mr. van der Wal’s leadership will enable the Company to build on its solid foundation of excellent customer service to achieve sustained growth and profitability. Forward-looking statements are not guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statement. These statements are based upon, among other things, assumptions made by, and information currently available to, management.  These and other risks are more fully described in the Company's filings with the Securities and Exchange Commission, including the Company's most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which should be read in conjunction herewith for a further discussion of important factors that could cause actual results to differ materially from those in the forward-looking statements.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

#

15350 Sherman Way, Suite 350, Van Nuys, CA  91406     ·      Phone 818.226.1968     ·      Fax 818.251.5300